The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Krasheninnikov A.A.

FGBU «Moskovskiĭ nauchno-issledovatelskiĭ onkologicheskiĭ institut im. P.A. Gertsena» Minzdrava Rossii

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Safronova E.Yu.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kalpinskiĭ A.S.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossiii

Kostin A.A.

Herzen Moscow Oncology Research Institute of Healthcare Ministry of the Russian Federation — branch of National Medical Research Radiology Center

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Drug therapy methods in patients with metastatic castration-resistant prostate cancer: Role of somatostatin analogues

Authors:

Krasheninnikov A.A., Niushko K.M., Safronova E.Yu., Kalpinskiĭ A.S., Kostin A.A., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2017;6(3): 76‑81

DOI: 10.17116/onkolog20176376-81

Read: 867 times

Download PDF (RU)
Contact the author
Table of contents

DRUG THERAPY METHODS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ROLE OF SOMATOSTATIN ANALOGUES
DRUG THERAPY METHODS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ROLE OF SOMATOSTATIN ANALOGUES

To cite this article:

Krasheninnikov AA, Niushko KM, Safronova EYu, Kalpinskiĭ AS, Kostin AA, Kaprin AD. Drug therapy methods in patients with metastatic castration-resistant prostate cancer: Role of somatostatin analogues. P.A. Herzen Journal of Oncology. 2017;6(3):76‑81. (In Russ.)
https://doi.org/10.17116/onkolog20176376-81

Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata

Prostate cancer (PC) is one of the most urgent problems of modern urologic oncology. More than 1.100.000 new prostate cancer cases are notified worldwide every year. The main treatment option in patients with metastatic PC is hormone therapy (HT) or a combination of chemotherapy and HT. Androgen deprivation therapy can achieve disease stabilization in more than 90% of patients, but the mean time to progression after hormone therapy in patients with metastatic PC is about 2 years. Then the patients who are observed to have a progressive tumor process with the remaining castration levels of testosterone get a stage of the so-called castration-resistant PC (CRPC). Disseminated CRPC is not only a poor prognostic disease, but also substantially worsens quality of life in the patients. The main mechanisms responsible for the development of CRPC include intraprostatic conversion of adrenal androgens to testosterone, as well as intratumoral androgen synthesis through enhanced expression of steroidogenic enzymes, such as cytochrome R450s17 (CYP17). The paper reviews current drug treatments in patients with CRPC.

Keywords:

castration-resistant prostate cancer
abiraterone
enzalutamide
cabazitaxel
docetaxel
octreotide
somatostatin
long-acting dosage forms of octreotide

Authors:

Krasheninnikov A.A.

FGBU «Moskovskiĭ nauchno-issledovatelskiĭ onkologicheskiĭ institut im. P.A. Gertsena» Minzdrava Rossii

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Safronova E.Yu.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kalpinskiĭ A.S.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossiii

Kostin A.A.

Herzen Moscow Oncology Research Institute of Healthcare Ministry of the Russian Federation — branch of National Medical Research Radiology Center

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

List of references:

  1. Kaprin AD, Starinskii VV, Petrova GV, eds. Malignant neoplasms in Russia in 2015 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2015 (zabolevaemost' i smertnost')]. Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMIRTs» Minzdrava Rossii; 2017. (In Russ.)
  2. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999—2007 by country and age: results of EUROCARE-5 — a population-based study. Lancet Oncol. 2014;15(1):23-34. doi:10.1016/s1470-2045(13)70546-1
  3. Lam J, Leppert J, Vemulapalli S, Shvarts O, Belldegrun A. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006;175(1):27-34. doi:10.1016/s0022-5347(05)00034-0
  4. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164(1):217-227. doi:10.1016/s0002-9440(10)63112-4
  5. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-4454. doi:10.1158/0008-5472.can-08-0249
  6. Titus M. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11(13):4653-4657. doi:10.1158/1078-0432.ccr-05-0525
  7. Scher H, Sawyers C. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253-8261. doi:10.1200/jco.2005.03.4777
  8. Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512. doi:10.1056/nejmoa040720
  9. de Bono J, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154. doi:10.1016/s0140-6736(10)61389-x
  10. Mostaghel E, Page S, Lin D, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033-5041. doi:10.1158/0008-5472.can-06-3332
  11. Stigliano A, Gandini O, Cerquetti L, et al. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol. 2007;194(1):55-61. doi:10.1677/joe-07-0131
  12. Stanbrough M. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66(5):2815-2825. doi:10.1158/0008-5472.can-05-4000
  13. Attard G, Belldegrun A, de Bono J. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96(9):1241-1246. doi:10.1111/j.1464-410x.2005.05821.x
  14. de Bono J, Logothetis C, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005. doi:10.1056/nejmoa1014618
  15. Ryan C, Smith M, de Bono J, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148. doi:10.1056/NEJMoa1209096
  16. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
  17. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733-1742. doi:10.1093/annonc/mdl105
  18. Salido M, Vilches J, Roomans G. Changes in elemental concentrations in LNCaP cells are associated with a protective effect of neuropeptides on etoposide-induced apoptosis. Cell Biol Int. 2004;28(5):397-402. doi:10.1016/j.cellbi.2004.03.008
  19. Yu D, Hsieh D, Chen H, Chang S. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications. J Urol. 2001;166(3):871-875. doi:10.1097/00005392-200109000-00016
  20. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer. 2000;88(11):2590-2597. doi:10.1002/1097-0142(20000601)88:11<2590::aid-cncr23>3.0.co;2-d
  21. Segal N, Cohen R, Haffejee Z, et al. BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med. 1994;118(6):616-618.
  22. Mitsiades CS, Bogdanos J, Karamanolakis D, et al. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res. 2006;26(5B):3693-700.
  23. Di Silverio F, Sciarra A. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation refractory prostate cancer. J Urol. 2003;170(5):1812-1816. doi:10.1097/01.ju.0000092480.71873.26
  24. Berezin PG, Milovanov VV, Ivannikov AA. Octreotide long in the treatment of patients with castration-refractory prostate cancer. Onkologiya. Zhurnal im. P.A. Gertsena. 2013;1:47-50. (In Russ.)
  25. Ganov DI, Varlamov SA. Experience with octreotide in patients with castration refractory prostate cancer. Onkourologiya. 2011;7(4):71-73. (In Russ.) doi:10.17650/1726-9776-2011-7-4-71-73
  26. Mishugin SV, Mordovin AA, Ganov VI, Varlamov SA, Gritskevich AA, Rusakov IG. Opyt primeneniya analoga somatostatina dlitel'nogo deistviya oktreotida pri lechenii kastratsionno-rezistentnogo raka predstatel'noi zhelezy. Onkologiya. Zhurnal im. P.A. Gertsena. 2016;1:31-35. (In Russ.) doi:10.17116/onkolog20165
  27. Kolesnikov GP, Semkov AS, Bystrov AA, Naumova IN. Analogi somatostatina v lechenii kastratsionnorezistentnogo raka predstatel'noi zhelezy: effektivnost' i perenosimost'. Onkourologiya. 2016;12(3):29-33. (In Russ.) doi:10.17650/1726-9776-2016-12-2-14-17

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.